Guangdong Maiheng Pharmaceutical R&D

Guangdong Maiheng Pharmaceutical R&D Co., Ltd. is a pharmaceutical research and development company based in Zhongshan, Guangdong, and serves as the dedicated R&D subsidiary of Guangdong Longfu Pharmaceutical. Established in 2020, the company focuses on the development of improved chemical drugs and high-quality generics, with a particular emphasis on sterile solutions and solid oral formulations. Its pipeline includes a sterile benzalkonium bromide solution currently under NDA review and a sterile magnesium sulfate solution in clinical development for the recovery of postpartum perineal trauma. Additionally, the company manages bioequivalence studies for products such as aceclofenac and apremilast. Maiheng utilizes the manufacturing infrastructure of its parent company to support the commercialization of its clinical-stage assets.